{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:11:53Z","timestamp":1776172313790,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04749-z","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:23:39Z","timestamp":1772879019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a nomogram for predicting progression from multidrug-resistant bacterial colonization to infection in lymphoma patients"],"prefix":"10.1007","volume":"17","author":[{"given":"Xin","family":"Ran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenling","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingsu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"4749_CR1","volume-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance[R]","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance[R]. Geneva: WHO; 2024."},{"key":"4749_CR2","doi-asserted-by":"publisher","first-page":"1382500","DOI":"10.3389\/fcimb.2024.1382500","volume":"14","author":"S Khafaja","year":"2025","unstructured":"Khafaja S, Salameh Y, Boutros CF, et al. Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients. Front Cell Infect Microbiol. 2025;14:1382500.","journal-title":"Front Cell Infect Microbiol"},{"key":"4749_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.13455\/j.cnki.cicor.113494-20230118-0032","volume":"30","author":"S Yuankai","year":"2023","unstructured":"Yuankai S, Qin Y, Haizhu C, et al. Clinical practice guideline for lymphoma in China (2023 version). Chin J Clin Oncol Rehabil. 2023;30:2\u201339. https:\/\/doi.org\/10.13455\/j.cnki.cicor.113494-20230118-0032.","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"4749_CR4","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil E, Justo JA et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis, 2024, ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"9","key":"4749_CR5","doi-asserted-by":"publisher","first-page":"e13594","DOI":"10.1111\/ctr.13594","volume":"33","author":"SM Pouch","year":"2019","unstructured":"Pouch SM, Patel G, AST Infectious Diseases Community of Practice. Multidrug-resistant Gram\u2010negative bacterial infections in solid organ transplant recipients\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13594.","journal-title":"Clin Transplant"},{"issue":"6","key":"4749_CR6","first-page":"488","volume":"71","author":"AK Nanayakkara","year":"2021","unstructured":"Nanayakkara AK, Boucher Hw, Fowler VG Jr, et al. Antibiotic resistance in the patient with cancer: escalating challenges and paths forward. CA Cancer J Clin. 2021;71(6):488\u2013504.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4749_CR7","first-page":"1","volume":"99","author":"SY Ong","year":"2024","unstructured":"Ong SY, Zain JM. Aggressive T-cell lymphomas: 2024 updates on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(1):1\u201318.","journal-title":"Am J Hematol"},{"issue":"6","key":"4749_CR8","first-page":"443","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, Desantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443\u201359.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4749_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"4749_CR10","volume-title":"National Healthcare Safety Network (NHSN) patient safety component manual[M]","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN) patient safety component manual[M]. Atlanta: CDC; 2024."},{"issue":"4","key":"4749_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAS.0000000000000323","volume":"39","author":"S Kato","year":"2015","unstructured":"Kato S, Asano N, Miyata-Takata T, et al. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases. Am J Surg Pathol. 2015;39(4):462\u201371.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4749_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/cid\/ciy153","volume":"67","author":"H Hakim","year":"2018","unstructured":"Hakim H, Dallas R, Wolf J, et al. Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia. Clin Infect Dis. 2018;67(4):541\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4749_CR13","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(20)30202-0","volume":"2","author":"EB Margolis","year":"2021","unstructured":"Margolis EB, Hakim H, Dallas RH, et al. Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis. Lancet Microbe. 2021;2(4):e159\u201367.","journal-title":"Lancet Microbe"},{"issue":"23","key":"4749_CR14","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","volume":"131","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK\/T cell lymphoma, nasal type. Blood. 2018;131(23):2528\u201340.","journal-title":"Blood"},{"issue":"2","key":"4749_CR15","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/HS9.0000000000000523","volume":"5","author":"JA Van Doesum","year":"2021","unstructured":"Van Doesum JA, Niezink AGH, Huls GA, et al. Extranodal natural killer\/T-cell lymphoma, nasal type: diagnosis and treatment. Hemasphere. 2021;5(2):e523.","journal-title":"Hemasphere"},{"issue":"17","key":"4749_CR16","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"WY Au","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931\u20137.","journal-title":"Blood"},{"issue":"2","key":"4749_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.13604\/j.cnki.46-1064\/r.2023.02.14","volume":"23","author":"Zhao-hong Chen","year":"2023","unstructured":"Chen Zhao-hong, Xiao-ping YOU, Yuan-yuan CAI, Bin WENG. Analysis of drug resistance and risk factors of multi drug resistant bacteria in bloodstream infection. China Trop Med. 2023;23(2):176\u201381. https:\/\/doi.org\/10.13604\/j.cnki.46-1064\/r.2023.02.14.","journal-title":"China Trop Med"},{"key":"4749_CR18","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41598-023-28270-3","volume":"13","author":"X Yang","year":"2023","unstructured":"Yang X, Guo R, Zhang B, et al. Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital. Sci Rep. 2023;13:2199.","journal-title":"Sci Rep"},{"issue":"2","key":"4749_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00134-022-06954-0","volume":"49","author":"L Kreitmann","year":"2023","unstructured":"Kreitmann L, Vasseur M, Jermoumi S, et al. Relationship between immunosuppression and intensive care unit-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter cohort study. Intensive Care Med. 2023;49(2):154\u201365.","journal-title":"Intensive Care Med"},{"issue":"6","key":"4749_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1470-2045(09)70069-5","volume":"10","author":"M Kamboj","year":"2009","unstructured":"Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10(6):589\u201397.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4749_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/jac\/dkq494","volume":"66","author":"C Gudiol","year":"2011","unstructured":"Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4749_CR22","doi-asserted-by":"publisher","first-page":"15622","DOI":"10.1038\/s41598-024-66524-w","volume":"14","author":"KH Park","year":"2024","unstructured":"Park KH, Jung YJ, Lee HJ, et al. Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections. Sci Rep. 2024;14(1):15622.","journal-title":"Sci Rep"},{"issue":"5","key":"4749_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, et al. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol. 2022;198(5):847\u201360.","journal-title":"Br J Haematol"},{"issue":"14","key":"4749_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1200\/JCO.2013.51.6963","volume":"32","author":"G Bucaneve","year":"2014","unstructured":"Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin\/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32(14):1463\u201371.","journal-title":"J Clin Oncol"},{"key":"4749_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fcimb.2015.00011","volume":"5","author":"R Moghnieh","year":"2015","unstructured":"Moghnieh R, estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon. Front Cell Infect Microbiol. 2015;5:11.","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04749-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:37:10Z","timestamp":1776170230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04749-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4749"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04749-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Chongqing University Cancer Hospital Hematological (Approval number: CZLS2023216-A), in accordance with the Declaration of Helsinki. Informed consent was waived by the Institutional Review Board of Chongqing University Cancer Hospital Hematological, because of the retrospective nature of the study, with all data anonymized for privacy protection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"563"}}